Aug 18, 2017
On August 3rd, I wrote a Blog titled” Advancing the Discipline of Cellular Orthopedics”. As readers of my weekly Blog as swell as present and former patients are aware, I have long focused my clinical practice first in joint replacement and now in Cellular Orthopedics, on the integration of patient care and research. When I traded the scalpel for a needle five years ago, I introduced that data collection and research methodology developed during my joint replacement career into the emerging discipline of Regenerative Medicine. Several months ago, I made a major decision to place increasing emphasis on that integration of patient care with research rather than continue to pursue the business model methodology. First the bad news, the diminution of marketing exposure inherent in my decision has temporarily resulted in a drop off in the number of procedures being performed. On the other hand, the international recognition of my efforts has culminated in an invitation to introduce the subspecialty of Cellular Orthopedics at the annual meeting of the Russian/ Ukrainian Orthopedic Association being held in St Petersburg, Russia, September 21st to 23rd. This meeting will be attended by over 1200 orthopedic surgeons from the region and it will be the first-time participants will have been introduced to non-operative alternatives for assisting a patient limited by arthritis of a major joint.
Sponsored by Zimmer-Biomet, Corporation, the largest prosthetic reconstructive company in the world, politics are set aside and the well-being of the human being becomes the only consideration. I am organizing my several presentations following the same educational principles I adhered to when I lectured in St Petersburg, Moscow and Vladivostok in 2004, 2005, and 2006. Then I shared my knowledge of joint replacement surgery and taught how I did things at Rush. Now I will share what I have learned in helping patients postpone, perhaps even avoid a joint replacement presenting at a workshop and then sharing my scientific outcomes data.
It is a personally rewarding opportunity for me as it is an international recognition of my initiatives and lends credence to my decision to have separated myself from the business model pursuit. Imagine my personal satisfaction to be returning by invitation to the birthplaces of my mother and father 85 years after they had been forced to leave? I am experiencing the ultimate reward from my profession.
If you want to personally gain from my Cellular Orthopedic experiences and knowledge, schedule an appointment buy calling 312-475-1893 or view my website and webinars www.ilcellulartherapy.com.
Tags: Bone Marrow Concentrate, cellular orthopedics, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Mesenchymal Stem Cell, Orthopedic Care, regenerative medicine, Russian/ Ukrainian Orthopedic Association, stem cell treatment, Zimmer-Biomet
Aug 4, 2017
Most readers know that I “graduated” from joint replacement surgery into an emerging field of Regenerative Medicine about five years ago. Prior to that time, I had dedicated 37 years to Reconstructive Orthopedic Surgery and played an active role in a joint replacement practice combining research with education as I improved the quality of life for my patients. By the end of my surgical career, I had authored more than 90 scientific papers in the field of hip and knee replacement as well serving in the leadership of the joint replacement program at a major medical center in Chicago.
That was “back in the day” of joint replacement surgery; but rather than live in the past, I have elected to partake in the present and advance Cellular Orthopedics into the future. I now have the largest and most comprehensive clinical outcomes data base in the United States concerning Bone Marrow Concentrate, Mechanical preparation of Adipose Graft, and Amniotic Fluid injection used in the treatment of knee arthritis. This information has allowed me, up until now, to make a scientifically based recommendation as to the best regenerative option for dealing with an arthritic joint.
In my initiative to advance the discipline of Cellular Orthopedics, the next innovation will be to offer a prior analysis of the stem cell content for the patient seeking the regenerative option as a means of postponing or avoiding a joint replacement. Should a patient present with osteoarthritis seeking to determine if she, he or hir will benefit from Adult Mesenchymal Stem Cells and Growth Factors, I am able to offer the equivalent of a bone marrow biopsy and determine the amount of viable cellular orthopedic content available in that individual’s bone marrow. My recommendations then would be based on actual number of cells and not on age related or disease influenced averages or estimates. Predictability of an individual’s outcome in determining whether to proceed with the regenerative intervention would be customized and not generalized. Where this scientific leap forward would be of particular interest includes patients over age 70, those who have received immune altering systemic management for a co-morbidity or for patients whose medication requirements up until now would have eliminated them from a regenerative consideration.
To learn more schedule an appointment 847 390 7666
You may access my web site and watch my Webinar at www.Ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, cellular orthopedics, Orthopedic Surgeon, Osteoarthritis, regenerative medicine, stem cell treatment
Jul 31, 2017
“Haven’t spoken with you in a few months so I thought you might be interested to hear about my knees since the January injections. Things are definitely better. The most important of which is my really bad left knee doesn’t lock up when I roll over in bed. It hurt so bad that it used to wake me up. That’s completely gone. As is the swelling even after walking 18 holes of golf and riding my bike 20 miles. It’s not completely without pain though. It tightens up. But I never have any residual pain in the mornings, even after walking 10 miles and cycling 70!
So, I just started a vegan diet. Was told by my new doctor (she’s in Chicago and does this concierge thing) that it’s anti-inflammatory and might help me get off cholesterol medicine. So far, it’s eliminating my knee pain and I’ve only been at it a week! Fingers crossed. I’ll let you know how things go. It’s not easy being vegan, but certainly easier in SF with a vegetarian wife than it would be in Chicago with a meat eater for a mate! Thanks again.”
Earlier this week, I received this message from a patient who I have been caring for over the last 24 months. It is very rewarding to my team and me when I learn about continued improvement following the initiation of cellular orthopedic interventions as an alternative to a major joint surgical reconstruction with the inherent risks of an adverse outcome. My practice is Outcome Focused based with a serious commitment to the clinical research required to continually confirm the efficacy of our menu of services. It is important that I maintain a leadership role in advancing the clinical science of the regenerative products that I use in my practice. As I have written before and about which I am constantly reminded, the regenerative process requires time. Sometimes it requires weeks and sometimes it takes months. On occasion, it may require more than one intervention.
The testimonial this week suggests a change in diet allowed my patient to discontinue statins with a resultant significant diminution in pain. Many patients inquire about supplements and foods that may make a difference. In addition, I find that those who partake in athletics and fitness, also contribute to their well-being and success of a regenerative intervention.
To join our team, call 847 390 7666
Or access our web site and watch the webinar ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, Interventional Orthopedics, stem cells
Jul 20, 2017
We now are approaching five-year outcomes regarding the use of Bone Marrow Concentrate for Osteoarthritis of the hip, knee, shoulder and ankle. Bone Marrow contains Adult Mesenchymal Stem (MSC) cells and Growth Factors. In the beginning, the entire informed consent process focused on the MSC in bone marrow as the agent responsible for diminishing pain, improving motion, stopping, at times reversing the progression of osteoarthritis, and potentially regenerating the joint itself. Now we know that equally important to the MSC are the growth factors produced and stored in the bone marrow. Some of the key proteins (Growth factors) include Interleukin-1 Receptor Antagonist Protein (IRAP), Alpha-2-Macroglobulin (A2M), fibrinogen, PDGF, VEGF, and TGF-B to name a few.
The reason we directed our clinical initiatives to Bone Marrow Concentrate is that while Amniotic Fluid contains Hyaluronic Acid, once harvested, sterilized and fast thawed for clinical application, there are no living stem cells left, so Amniotic Fluid Concentrate has no regenerative potential. When it comes to Adipose Derived Stem Cells, in order to liberate the stem cell from the adipocyte, an enzyme, collagenase must be employed. The latter is not approved by the FDA. Additionally, there is no evidence of Growth Factor content in adipose derived tissue.
While I have blogged about the superiority of Bone Marrow Concentrate over all other non-surgical approaches for arthritis, the introduction of the intraosseous adjunct, subchondroplasty, is resulting in even superior outcomes when compared to those who were treated prior to this contemporary version of Cellular Orthopedics. It has been nine months basically since I started injecting Bone Marrow Concentrate into the marrow adjacent to the joint in addition to the intraarticular approach. We already are seeing a better outcome in those who availed themselves of the Intraosseous adjunct. Up until eight weeks ago, my ability to offer contemporary and improved treatment options was limited by preexisting contractual obligations; but now unrestricted, I have expanded my scope of offerings including elevation of subchondroplasty from a clinical trial status to usual and customary adjunct standard of practice option. As well, I now offer an increased opportunity for participation in other clinical trials for the arthritic joint when a patient meets obligatory inclusion criteria determined by the trial sponsor.
If you want to postpone, perhaps avoid a major surgical replacement for an arthritic joint, call for a consultation 847 390 7666
You may visit my web site at IlCellulartherapy.com where you may watch my webinar.
Tags: arthritis, Benefits and Risk, bone marrow, Bone Marrow Concentrate, Clinical Studies, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Microfracture surgery, Orthopedics, Osteoarthritis, Pain Management, stem cells, treatment
Jul 13, 2017
Last week, we traveled to Israel to celebrate the wedding of our youngest son. Israel became the destination for the event as Eric and Judith had met there while his music business was subcontracting to Coke and Judith led the International Marketing initiatives for Coke. The event took place on July 5th, at an organic farm in the outskirts of Jerusalem. In such a majestic and historical setting prior to and after the ceremony, there took place several organized tours including one of Jerusalem, another at the Dead Sea and for several, a trip to Petra. It was a relatively small group of the attendees; one in particular, a very close and long-time friend has been the subject of my Blog in years past as I described his return to skiing, biking and fly fishing following a Bone Marrow Concentrate/Growth Factor Concentrate/Stem Cell concentrate intervention. Prior to those procedures, he had been forced to give up his athletic passions for several years because of the limitations imposed by arthritis of both knees.
Above is his activity score from Monday, July 3, when Bob and his wife toured Jerusalem’s Old City including a hike on the ramparts of the wall surrounding the Christian Quarter, the stop and prayer at the Temple Mount and a shopping spree at the Arab Suk (bazaar).
What Bob represents is the potential for continued improvement over several years following a regenerative intervention, a process of which I am continually reminded as time passes and I have a longer follow up of my patients. Our mission and ethos is to help patients with arthritic joints enjoy an active life style and postpone, perhaps avoid joint replacements when arthritic impairment ensues. The documentation from the patient above is one of improving outcome as time passes. While his is an anecdote, our data base increasingly reflects similar happenings for the majority of our patients.
There are now many providers for those with arthritic impairment seeking improved function and less symptoms; and who are not candidates for a joint replacement or who do not want to undergo the major surgical undertaking. In your choice of an Interventional Cellular specialist, inquire about her or his long-term outcomes; not just “will I get a free lunch if I attend a seminar?”
To learn more, call for a consultation 847 390 7666
You may watch my webinar and learn more by visiting my website at Ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, joint replacement, Knee Pain Relief, Orthopedic Surgeon, Regenerative, stem cells
